Asylia Diagnostics is developing molecular diagnostics tests to predict hyperprogressive disease (HPD) in patients receiving immune checkpoint inhibitors. HPD leads to the rapid mortality of patients and is an unmet clinical need. Asylia's AI-powered intelligent platform and knowledge base for discovery and development of molecular biomarkers allows predicting safety risks for all solid tumors targeted by immunotherapy.